Inhibikase Therapeutics (NASDAQ:IKT) is a clinical-stage pharmaceutical company focused on developing therapies for neurodegenerative diseases, notably Parkinson's disease and related disorders. By targeting the underlying pathologies that contribute to these conditions, Inhibikase aims to halt or slow their progression. The company's pipeline includes projects that explore innovative treatment approaches, leveraging kinase inhibition strategies to potentially safeguard neuronal function and improve outcomes for patients facing these challenging diseases. Their objective is to transform the therapeutic landscape for neurodegenerative disorders through science-driven innovation, offering hope to patients and families affected by these debilitating conditions.